Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$111.70 -0.5%	$106.55	$72.21 ▼ $139.13	$5.53B	0.46	666,483 shs	453,651 shs
LNTH Lantheus	$70.18 -4.6%	$78.80	$69.12 ▼ $118.71	$5.09B	0.12	980,999 shs	1.35 million shs
RYTM Rhythm Pharmaceuticals	$89.20 -1.6%	$67.14	$40.61 ▼ $94.80	$5.77B	2.26	590,318 shs	624,068 shs
TVTX Travere Therapeutics	$16.11 -2.4%	$15.87	$7.93 ▼ $25.29	$1.47B	0.72	1.61 million shs	1.44 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	-0.48%	+2.50%	+8.56%	+6.93%	+33.39%
LNTH Lantheus	-4.65%	-13.69%	-11.15%	-30.73%	-42.29%
RYTM Rhythm Pharmaceuticals	-1.63%	+2.88%	+45.09%	+44.48%	+71.27%
TVTX Travere Therapeutics	-2.42%	-2.19%	+11.80%	+7.98%	+56.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.7215 of 5 stars	4.5	1.0	4.5	2.5	4.2	0.6
LNTH Lantheus	4.6184 of 5 stars	3.4	2.0	4.2	3.3	2.5	1.9
RYTM Rhythm Pharmaceuticals	3.1846 of 5 stars	2.5	1.0	4.3	2.6	0.8	0.6
TVTX Travere Therapeutics	3.6961 of 5 stars	4.4	5.0	0.0	2.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	54.28% Upside
LNTH Lantheus	2.83	Moderate Buy	$131.20	86.95% Upside
RYTM Rhythm Pharmaceuticals	3.07	Buy	$91.93	3.06% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$32.14	99.52% Upside

Current Analyst Ratings Breakdown

Latest TVTX, LNTH, RYTM, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$92.00 ➝ $105.00
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/10/2025	RYTM Rhythm Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/10/2025	RYTM Rhythm Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$76.00 ➝ $110.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $95.00
7/10/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$91.00 ➝ $129.00
7/10/2025	RYTM Rhythm Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$97.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$95.00
7/9/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00 ➝ $95.00
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	RYTM Rhythm Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$88.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	14.26	N/A	N/A	$1.18 per share	94.66
LNTH Lantheus	$1.53B	3.17	$6.76 per share	10.38	$15.65 per share	4.48
RYTM Rhythm Pharmaceuticals	$130.13M	43.61	N/A	N/A	$0.35 per share	254.86
TVTX Travere Therapeutics	$233.18M	6.14	N/A	N/A	$0.76 per share	21.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	39.61	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	19.94	11.12	N/A	16.55%	36.99%	20.55%	7/30/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
TVTX Travere Therapeutics	-$321.55M	-$2.81	N/A	N/A	N/A	-82.88%	-1,179.73%	-41.10%	7/30/2025 (Estimated)

Latest TVTX, LNTH, RYTM, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	TVTX Travere Therapeutics	-$0.26	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	RYTM Rhythm Pharmaceuticals	-$0.64	N/A	N/A	N/A	$43.72 million	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
7/30/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
LNTH Lantheus	0.49	5.74	5.46
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
TVTX Travere Therapeutics	9.46	2.05	2.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
LNTH Lantheus	99.06%
RYTM Rhythm Pharmaceuticals	N/A
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
LNTH Lantheus	1.50%
RYTM Rhythm Pharmaceuticals	6.10%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
TVTX Travere Therapeutics	460	88.81 million	85.08 million	Optionable

TVTX, LNTH, RYTM, and AXSM Headlines

Recent News About These Companies

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 18 at 3:17 AM | marketbeat.com

Research Analysts Set Expectations for TVTX FY2025 Earnings

July 18 at 2:39 AM | americanbankingnews.com

Wedbush Forecasts Reduced Earnings for Travere Therapeutics

July 17 at 6:31 AM | marketbeat.com

Q2 EPS Estimates for Travere Therapeutics Lowered by Wedbush

July 17 at 3:24 AM | americanbankingnews.com

Wedbush Expects Lower Earnings for Travere Therapeutics

July 16 at 7:16 AM | marketbeat.com

Emerald Advisers LLC Lowers Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 13, 2025 | marketbeat.com

Emerald Mutual Fund Advisers Trust Increases Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

July 12, 2025 | marketbeat.com

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 11, 2025 | businesswire.com

109,542 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by Penserra Capital Management LLC

July 8, 2025 | marketbeat.com

Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

July 6, 2025 | insidermonkey.com

Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

July 6, 2025 | msn.com

Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 815 Shares of Stock

July 3, 2025 | insidertrades.com

Q2 EPS Estimate for Travere Therapeutics Cut by Analyst

July 3, 2025 | marketbeat.com

Jula Inrig Sells 815 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

July 2, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

July 2, 2025 | prnewswire.com

1TVTX : Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews

July 2, 2025 | benzinga.com

Travere Therapeutics (NASDAQ:TVTX) Given Buy Rating at HC Wainwright

July 1, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX - Morningstar

June 29, 2025 | morningstar.comM

Travere Therapeutics Inc News (TVTX) - Investing.com

June 27, 2025 | investing.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

June 23, 2025 | globenewswire.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Brokerages

June 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVTX, LNTH, RYTM, and AXSM Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$111.70 -0.54 (-0.48%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$111.42 -0.28 (-0.25%)

As of 07/18/2025 06:52 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Lantheus NASDAQ:LNTH

$70.18 -3.42 (-4.65%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$70.92 +0.73 (+1.05%)

As of 07/18/2025 07:59 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Rhythm Pharmaceuticals NASDAQ:RYTM

$89.20 -1.48 (-1.63%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$90.39 +1.19 (+1.33%)

As of 07/18/2025 07:55 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Travere Therapeutics NASDAQ:TVTX

$16.11 -0.40 (-2.42%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$16.11 +0.00 (+0.03%)

As of 07/18/2025 04:33 PM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time